S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)

Nkarta (NKTX) Stock Forecast, Price & News

$1.50
-0.19 (-11.24%)
(As of 09/28/2023 ET)
Compare
Today's Range
$1.48
$1.64
50-Day Range
$1.59
$2.29
52-Week Range
$1.48
$14.57
Volume
910,190 shs
Average Volume
457,425 shs
Market Capitalization
$73.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.67

Nkarta MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
1,144.4% Upside
$18.67 Price Target
Short Interest
Bearish
6.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$2,436 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.77) to ($2.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

461st out of 969 stocks

Pharmaceutical Preparations Industry

207th out of 455 stocks


NKTX stock logo

About Nkarta (NASDAQ:NKTX) Stock

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

NKTX Price History

NKTX Stock News Headlines

Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
H.C. Wainwright Keeps Their Buy Rating on Nkarta (NKTX)
The Latest Analyst Ratings for Nkarta
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Needham Keeps Their Buy Rating on Nkarta (NKTX)
Analyst Expectations for Nkarta's Future
Why Shares of Nkarta Are Slumping Tuesday
See More Headlines
Receive NKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter.

NKTX Company Calendar

Last Earnings
8/10/2023
Today
9/28/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NKTX
Fax
N/A
Employees
169
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.67
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+1,144.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-113,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.63 per share

Miscellaneous

Free Float
46,311,000
Market Cap
$73.59 million
Optionable
Not Optionable
Beta
-0.06
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Paul J. HastingsMr. Paul J. Hastings (Age 63)
    CEO, Pres & Director
    Comp: $938.41k
  • Dr. Alicia J. Hager (Age 53)
    Chief Legal Officer & Corp. Sec.
    Comp: $590.94k
  • Ms. Alyssa Levin C.A. (Age 38)
    CPA, Chief Financial & Bus. Officer and Principal Accounting Officer
  • Dr. Ralph Brandenberger Ph.D. (Age 54)
    Chief Technical Officer
  • Dr. James Trager Ph.D. (Age 59)
    Ph.D., Chief Scientific Officer
  • Ms. Yvonne Li M.B.A. (Age 63)
    Chief Admin. Officer
  • Mr. Greg Mann
    VP of Public Affairs and Investor Relations
  • Dr. David R. Shook M.D. (Age 45)
    Chief Medical Officer













NKTX Stock - Frequently Asked Questions

Should I buy or sell Nkarta stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NKTX shares.
View NKTX analyst ratings
or view top-rated stocks.

What is Nkarta's stock price forecast for 2023?

5 brokers have issued 1 year target prices for Nkarta's shares. Their NKTX share price forecasts range from $15.00 to $26.00. On average, they expect the company's share price to reach $18.67 in the next year. This suggests a possible upside of 1,144.4% from the stock's current price.
View analysts price targets for NKTX
or view top-rated stocks among Wall Street analysts.

How have NKTX shares performed in 2023?

Nkarta's stock was trading at $5.99 at the beginning of the year. Since then, NKTX stock has decreased by 75.0% and is now trading at $1.50.
View the best growth stocks for 2023 here
.

When is Nkarta's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our NKTX earnings forecast
.

How were Nkarta's earnings last quarter?

Nkarta, Inc. (NASDAQ:NKTX) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.01.

What other stocks do shareholders of Nkarta own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Block (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND), Citigroup (C), Salesforce (CRM), CVS Health (CVS) and DraftKings (DKNG).

When did Nkarta IPO?

(NKTX) raised $150 million in an IPO on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO.

What is Nkarta's stock symbol?

Nkarta trades on the NASDAQ under the ticker symbol "NKTX."

Who are Nkarta's major shareholders?

Nkarta's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (9.63%), BlackRock Inc. (6.20%), Geode Capital Management LLC (1.35%), State Street Corp (1.22%), JPMorgan Chase & Co. (0.78%) and Barclays PLC (0.77%). Insiders that own company stock include David Shook, Dawn N Edwards, James Trager, Kanya Rajangam, Nadir Mahmood, Paul J Hastings, Paul J Hastings, Ra Capital Management, LP, Ralph Brandenberger and Simeon George.
View institutional ownership trends
.

How do I buy shares of Nkarta?

Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nkarta's stock price today?

One share of NKTX stock can currently be purchased for approximately $1.50.

How much money does Nkarta make?

Nkarta (NASDAQ:NKTX) has a market capitalization of $73.59 million. The company earns $-113,840,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.

How many employees does Nkarta have?

The company employs 169 workers across the globe.

How can I contact Nkarta?

Nkarta's mailing address is 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.nkartatx.com. The company can be reached via phone at 925-407-1049 or via email at gmann@nkartatx.com.

This page (NASDAQ:NKTX) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -